Karuna Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides General Business Update
Two Phase 3 trials, EMERGENT-2 and EMERGENT-4, initiated evaluating KarXT for the treatment of psychosis
Two Phase 3 trials, EMERGENT-2 and EMERGENT-4, initiated evaluating KarXT for the treatment of psychosis